GlassScriptPhysician profile
Andrea Ward
NPI 1427391853
$1,186.75
in general payments reported to CMS, 2019-2025
30 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $17.60 · 2021: $97.70 · 2022: $286 · 2023: $141 · 2024: $155 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.77 | 2019-2025 | Ubrelvy, Qulipta |
| Abbott Laboratories | $158.93 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $99.83 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $87.43 | 2022-2025 | |
| Corcept Therapeutics | $71.97 | 2025 | Korlym |
| Coloplast Corp | $57.13 | 2022 | |
| Xeris Pharmaceuticals, INC. | $44.24 | 2024-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $41.85 | 2023-2024 | Veozah |
| Ardelyx, INC. | $41.36 | 2025 | Ibsrela |
| Exact Sciences Corporation | $40.85 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $34.47 | 2022-2025 | Heplisav-B |
| Coopersurgical, INC. | $28.28 | 2019 | |
| Amgen INC. | $25.97 | 2022 | |
| Meditrina | $25.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.05 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.34 | 2022 | |
| Pfizer INC. | $18.26 | 2024 | |
| Hologic Sales and Service, LLC | $17.60 | 2020 | |
| Amag Pharmaceuticals, INC. | $17.02 | 2019 | |
| Glaxosmithkline, LLC. | $16.71 | 2025 | Arexvy, Shingrix |
| Aimmune Therapeutics, INC. | $16.67 | 2025 | Zenpep |
| Lilly USA, LLC | $15.23 | 2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $14.55 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $14.33 | 2021 | |
| Mayne Pharma Commercial LLC | $13.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.62 | 2022 | |
| Merck Sharp & Dohme LLC | $13.25 | 2019 | |
| Therapeuticsmd, INC. | $12.99 | 2019 | |
| Phadia US INC. | $11.84 | 2021 | |
| Organon LLC | $3.19 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.